Please assess the completion status of the following clinical trial:

Trial Title: Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have clinical symptoms consistent with AMI (e.g., angina or anginal equivalent)lasting \>20 minutes but \<12 hours in duration;~* ST-segment elevation of \>1 mm in \>2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \>1 mm in \>2 contiguous anterior leads;~* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent.~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications:~  * Heparin, pork or pork products~ * Both abciximab and eptifibatide~ * Aspirin~ * Both Clopidogrel and Ticlopidine~ * Bivalirudin~ * Paclitaxel or Taxol~ * The polymer components of the TAXUS™ stent (SIBS)~ * Stainless steel and/or~ * Contrast media;~* Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, low molecular weight heparin or fondaparinux for this admission. Patients receiving prior unfractionated heparin may be enrolled, and treated per randomization;~* Current use of coumadin;~* Systemic (intravenous) Paclitaxel or Taxol use within 12 months;~* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study;~* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;~* History of intra-cerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke;~* Stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect;~* Gastrointestinal or genitourinary bleeding within the last 2 months, or major surgery within six weeks;~* Recent history or known current platelet count \<100,000 cells/mm3 or Hgb \<10 g/dL;~* Extensive peripheral vascular disease, such that emergent angiography and intervention in the opinion of the investigator is likely to be difficult or complicated;~* An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment;~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance;~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period;~* Previous enrollment in this trial;~* Patients who underwent coronary stent implantation within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pharmacology Arm (Type: ACTIVE_COMPARATOR): To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~1. reduced rates of major bleeding events at 30 days~2. similar rates of major adverse ischemic cardiac events at 30 days~3. reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days.
- Stent Arm (Type: ACTIVE_COMPARATOR): To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~1. reduced rates of target lesion revascularization for ischemia at 1 year~2. similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~3. lower rates of analysis segment binary angiographic restenosis at 13 months

Based on this trial design, predict the completion outcome and termination type (if applicable).